Association of IVCF and brain metastases with 180-day ICH among patients diagnosed with melanoma, kidney, breast, or lung cancers and a VTE event by the cancer bleeding risk
| Variable . | HR (95% CI) . |
|---|---|
| Overall cohort∗ | |
| Brain metastases | |
| Yes | 5.14 (2.99-8.83) |
| No | Reference |
| IVCF | |
| Yes | 1.20 (0.77-1.88) |
| No | Reference |
| Variable . | HR (95% CI) . |
|---|---|
| Overall cohort∗ | |
| Brain metastases | |
| Yes | 5.14 (2.99-8.83) |
| No | Reference |
| IVCF | |
| Yes | 1.20 (0.77-1.88) |
| No | Reference |
There was no interaction between IVCF and brain metastases (P = .9535). A propensity-matched conditional Cox proportional hazard regression model was used. The model was adjusted for the year of VTE diagnosis, sex, race/ethnicity, and active bleeding ≤14 days before the index VTE admission date.